Development of Extraintestinal Manifestations in Pediatric Patients with Inflammatory Bowel Disease

被引:145
|
作者
Jose, Folashade Adebisi [1 ]
Garnett, Elizabeth A. [1 ]
Vittinghoff, Eric [1 ]
Ferry, George D. [1 ]
Winter, Harland S. [1 ]
Baldossano, Robert N. [1 ]
Kirschner, Barbara S. [1 ]
Cohen, Stanley A. [1 ]
Gold, Benjamin D. [1 ]
Abramson, Oren [1 ]
Heyman, Melvin B. [1 ]
机构
[1] Dept Pediat Gastroenterol Hepatol & Nutr, San Francisco, CA USA
关键词
children; adolescents; ulcerative colitis; Crohn's disease; arthritis; sclerosing cholangitis; PRIMARY SCLEROSING CHOLANGITIS; ULCERATIVE-COLITIS; CROHNS-DISEASE; PREVALENCE; OSTEOPOROSIS; CHILDREN;
D O I
10.1002/ibd.20604
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Extraintestinal manifestations (EIMs) in Pediatric patients with inflammatory bowel disease (IBD) are poorly characterized. We examined the prevalence of EIMs at diagnosis. subsequent incidence. and risk factors for EIMs. Methods: Data for 1649 patients from the PediIBD Consortium Registry, diagnosed with IBD before 18 years of age (1007 [61%] with Crohn's disease, 471 [29%] with ulcerative colitis, and 171 [10%] with indeterminate colitis), were analyzed using logistic regression, Kaplan-Meier, log rank tests, and Cox models. Results: EIMs were reported prior to IBD diagnosis in 97 of 1649 patients (6%). Older children at diagnosis had higher rates compared with younger children. and arthritis (26%) and aphthous stomatitis (21 %) were most common. Among the 1552 patients without EIM at diagnosis, 290 developed at least 1 EIM. Kaplan-Meier estimates of cumuative incidence were 9% at 1 year. 19% at 5 years. and 29% at 15 years after diagnosis. Incidence did not differ by IBD type (P = 0.20), age at diagnosis (P = 0.22). or race/ethnicity (P = 0.24). Arthritis (17%) and osteopenia/osteoporosis (15%) were the most common EIMs after IBD diagnosis. Conclusions: In our large cohort of pediatric IBD patients, 6% had at least 1 EIM before diagnosis of IBD. At least 1 EIM will develop in 29% within 15 years of diagnosis. The incidence of EIMs both before and after diagnosis of IBD differs by type of EIM and may be slightly higher in girls, but is independent of the type of IBD, age at diagnosis, and race/ethnicity.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [41] Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Gonczi, Lorant
    Golovics, Petra Anna
    Lovasz, Barbara Dorottya
    Szita, Istvan
    Balogh, Mihaly
    Pandur, Tunde
    Vavricka, Stephan R.
    Rogler, Gerhard
    Lakatos, Laszlo
    Lakatos, Peter Laszlo
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (07) : 848 - 854
  • [42] The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease
    Turkcapar, N
    Toruner, M
    Soykan, I
    Aydintug, OT
    Cetinkaya, H
    Duzgun, N
    Ozden, A
    Duman, M
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (07) : 663 - 668
  • [43] IMPACT OF EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE: A COHORT OF SICILIAN PATIENTS
    Scrivo, B.
    Ingrassia, G.
    Busacca, A.
    Calvaruso, V.
    Cappello, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2019, 51 : E241 - E241
  • [44] Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients
    Zippi, Maddalena
    Corrado, Claudia
    Pica, Roberta
    Avallone, Eleonora Veronica
    Cassieri, Claudio
    De Nitto, Daniela
    Paoluzi, Paolo
    Vernia, Piero
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (46) : 17463 - 17467
  • [45] Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients
    Bandyopadhyay D.
    Bandyopadhyay S.
    Ghosh P.
    De A.
    Bhattacharya A.
    Dhali G.K.
    Das K.
    [J]. Indian Journal of Gastroenterology, 2015, 34 (5) : 387 - 394
  • [46] The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease
    Nuran Turkcapar
    Murat Toruner
    Irfan Soykan
    Olcay Tiryaki Aydintug
    Hulya Cetinkaya
    Nursen Duzgun
    Ali Ozden
    Murat Duman
    [J]. Rheumatology International, 2006, 26 : 663 - 668
  • [47] Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
    Jurij Hanzel
    Christopher Ma
    Niels Vande Casteele
    Reena Khanna
    Vipul Jairath
    Brian G. Feagan
    [J]. Drugs, 2021, 81 : 1697 - 1697
  • [48] EXTRAINTESTINAL AND SYSTEMIC MANIFESTATIONS OF INFLAMMATORY BOWEL-DISEASE
    RANKIN, GB
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1990, 74 (01) : 39 - 50
  • [49] Extraintestinal Manifestations in Children Diagnosed with Inflammatory Bowel Disease
    Kavcar, Zubeyr
    Civan, Hasret Ayyildiz
    Taskin, Didem Gulcu
    Hatipoglu, Sadik Sami
    [J]. MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2023, 57 (01): : 73 - 78
  • [50] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
    Livne-Margolin, M.
    Ling, D.
    Konyo, S. Attia
    Haj, O.
    Abitbol, C. M.
    Ben-Horin, S.
    Kopylov, U.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I429 - I430